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Abstract
This review updates the recent advances and applications of three prominent synchrotron
radiation techniques, microprobe X-ray fluorescent spectroscopy/imaging, X-ray absorption
spectroscopy and infrared microspectroscopy, and highlights how these tools are useful to the
medicinal chemist. A brief description of the principles of the techniques is given with
emphasis on the advantages of using synchrotron radiation-based instrumentation rather than
instruments using typical laboratory radiation sources. This review focuses on a number of
recent applications of these techniques to solve inorganic medicinal chemistry problems,
focusing on studies of cellular uptake, distribution and biotransformation of established and
potential therapeutic agents. The importance of using these synchrotron-based techniques to
assist the development, or validate the chemistry behind, drug design is discussed.
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Introduction
The cellular uptake, distribution and biotransformations associated with administration of a
therapeutic agent are all crucial information for the medicinal chemist as they assist the
design, understanding and development of a pharmaceutical. Importantly, the inorganic
medicinal chemist can exploit the detection sensitivity and capabilities that synchrotron
radiation techniques such as X-ray fluorescence (XRF) spectroscopy and X-ray absorption
spectroscopy (XAS) possess for the detection and characterisation, respectively, of trace
metals/metalloids associated with metallo-/metalloid- containing therapeutics in biological
systems or fluids. While there are exceedingly sensitive analytical techniques available for
this use such as high performance liquid chromatography (HPLC), graphite furnace atomic
absorption spectrophotometry (GFAAS) and inductively-coupled plasma-mass spectrometry
(ICP-MS),[1-2] these techniques fail to provide crucial spatial information regarding a drug in
a tissue or cell. Also, in most cases the sample preparation (such as solvent extractions or
acid

digestion)

associated

with

these

techniques

does

not

preserve

important

features/information such as the biological structure and/or the chemical speciation/structure
of the drug or its metabolites.[1-2] As such, synchrotron radiation techniques such as
microprobe XRF and XAS, offer unique advantages over laboratory-based techniques, as will
be discussed in the following sections. While there are other microprobe techniques capable
of relatively sensitive imaging, these are not the focus of this review and the reader is referred
to the following references for information on these techniques.[3-5] In addition to XRF and
XAS analysis of biological systems, synchrotron radiation-Fourier transform infrared (SRFTIR) microspectroscopy has recently shown promise for rapid, high quality and high
throughput analysis of biological samples, particularly cell samples. The latest applications of
this technique for monitoring biomolecular changes associated with drug administration will
be described.
3

Microprobe X-Ray Fluorescence Imaging
XRF spectroscopy is an analytical technique which involves the detection of emitted
characteristic X-rays following excitation of the elements within the sample.[6-9]

While

electron, particle (protons or alpha particles), or X-ray beams can be employed as the exciting
source for this analysis, the use of X-ray beams (from a synchrotron source) has been
instrumental in the advancement of the technique in the area of microprobe XRF imaging for
inorganic medicinal chemistry purposes.[5,8,10-11] Synchrotron radiation X-ray fluorescence
(SRXRF) spectroscopy, also known as synchrotron radiation induced X-ray emission
(SRIXE) spectroscopy, has become competitive with the earlier microprobe and nanoprobe
techniques following the development of X-ray focusing devices, such as the KirkpatrickBaez (KB) mirror and the zone plate, that are capable of micron and submicron resolution,
respectively.[12-15] There are two important features that contribute to the superb elemental
sensitivities of microprobe SRXRF: (i) the absence of the continuum (bremsstrahlung)
background radiation that is a feature of spectra obtained from charged particle beams, and
(ii) the increased X-ray flux on the sample associated with the use of third generation
synchrotron facilities.[5,16-18] Detection sensitivities have been reported in the ppb range, with
values of 1017g - 1014 g (depending on the particular element) cited for analysis of samples
as small as individual mammalian (or even bacterial) cells.[6,16-22]
The physical process of XRF spectroscopy (Figure 1) involves the use of a beam that
possesses an energy high enough to excite the atoms of all the elements of interest (i.e.,
higher than the binding energy of the core electron of the element, generally K and L
shells).[6-7] When the beam strikes the sample and a core electron is ejected into the
continuum, an unstable ion is produced. An electron, from an outer energy level, drops down
to fill the resultant vacancy and this is accompanied by the emission of an X-ray photon. The
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energy of the X-ray photon is equal to the energy difference in the initial and final states of
the transferred electron.[6-7] Since the electron transitions obey specific selection rules, the
differences in energy levels are discrete and characteristic for a particular element, giving rise
to characteristic X-rays that provide a unique identification for each element.[6,10,23] Binding
energies and characteristic X-rays are documented for almost all elements (Z95) of the
periodic table.[23] Most commonly, K and L lines are studied since the M and N line series
are often masked by competing Auger interference.[6,8]
While XRF spectra can be collected at point locations within a sample, it is the mapping
capabilities that are useful for studying the targeting action and metabolism of inorganic
therapeutic agents within biological samples ranging from tumours to individual cancer
cells.[3-4,24] The elemental imaging is performed by using a high precision XYZ motorized
stage (up to 0.05 microns spatial resolution) that scans the sample in a rastor pattern in the
path of the spatially fixed beam.[8,25-26] The sample is housed in a He or N2 atmosphere to
reduce the measurable component of Ar which is found in air. This is important for analysis
of biological samples since the spectral position of the Ar K-shell fluorescence peak occurs in
the region of P, S, Cl and K which are important endogenous elements.[8] Of the two gases,
however, He is the preferred gas given that there will be close to no absorption of the emitted
X-rays, whilst N2 gas will absorb significantly (40% of 2 keV X-rays) in a 1-cm path.[27]
Microprobe XRF imaging of a metal-containing drug within a biological sample
directly probes the metal based on the fundamental nature of the element. As such there is no
need to tag or radiolabel the drug. [6,28] In the instance of detecting intracellular elements that
are also endogenous, it is important that the introduced element is at significantly higher
concentrations than in the control. Various sample forms can be studied depending on the
required outcome.[8] Minimal sample preparation/interference is preferred when microprobe
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SRXRF is combined with other techniques such as microprobe XAS or SRFTIR
microspectroscopy, so that the integrity of the chemical structures within the sample are
maintained. Samples such as cells or tissue can be grown or deposited on spectroscopically
silent substrates, ideally silicon nitride membranes, formvar foils or polycarbonate foils

[8,28-

29]

. Often rapid freezing/cryofixation and freeze-drying of tissue or cells are the protocols

used for preparation of samples associated with XAS analysis.[8,15,19,28,30-34] Microprobe
SRXRF analysis has also been performed on whole cells grown on silicon nitride membranes
following fixation using glutaraldehyde or methanol.[35-36] For elements/drugs that possess
reasonably strong interactions with intracellular biomolecules, thin-section analysis is
beneficial as it facilitates high resolution imaging which is required for differentiation of
organelles and provides confirmation of cell membrane penetration of the drug. The protocol
for preparation of thin sections includes chemical fixation (e.g., the use of glutaraldehyde in
preference to formalin), dehydration, and resin infiltration.

[8,28,32,34,37]

The procedure is

similar to that used for preparation of samples for transmission electron microscopy since it
preserves the ultrastructure of the sample.[8,28,32,37] Details of these procedures are described
in the referenced publications.[8,28,32,37] Unfortunately, no procedure for preparation of whole
or thin-sectioned cells is free of uncertainty, which is why hydration and cryo-analysis, in the
form of X-ray microtomography promises to be the desired micro-imaging technique in the
future (see later Section).
Platinum-Containing Anti-Cancer Agents
Microprobe SRXRF imaging has been successfully used to probe the action of established
and potential anti-cancer drugs.[26,38] One of the most studied class of drugs includes the
platinum-containing drugs.

This is unsurprising due to the therapeutic significance of

cisplatin, carboplatin and oxaliplatin which are used in the treatment regimes of more than
half of all cancer patients receiving chemotherapy.[38-39]
6

Since the Pt L peaks (Pt L1 = 9.44 keV, Pt L2 = 9.361 keV) coexist with that of the
Zn K peak (Zn K1 = 9.572 keV), there are two approaches to the analysis of Pt in biological
samples.[26,38] The first is the estimation of the Zn K contribution to the Pt L based on the
known ratio of the Zn K peaks to the Zn K peak, followed by the subtraction of this value
from the Pt L peaks.[26] The second approach is to perform the experiment at a higher
energy (13.6 keV) that includes the Pt L peaks in the emitted X-rays and use these to
estimate the Pt concentration.[38]
Microprobe SRXRF studies of cisplatin-treated A2780 ovarian carcinoma cells revealed
predominant localisation of Pt in the nucleus with a small amount in the cytoplasm following
24 h exposure.[33] The uptake of Pt(II) and Pt(IV) potential anti-cancer agents by the A2780
cells with the metallointercalator, cis-[PtCl2(2-[(3-aminopropyl)amino]-9,10-anthracenedione)(NH3)], revealed a high colocalisation of Pt and P maps which was attributed to Pt
localisation in the cell nucleus.[38] A study of Br-labeled Pt(II) and Pt(IV)-treated cells was
performed to probe the mechanisms of Pt anti-cancer activity. In the first instance, one of the
amine ligands of cisplatin was substituted with a 3-bromopyridine ligand. Microprobe XRF
analysis of the Pt(II)-treated cells showed colocalisation of Pt and Br in the nucleus.[38-39]
The authors concluded that the coexistence of Br (as a brominated amine ligand) and Pt
confirmed the strongly held belief that the amine ligands are non-leaving groups of Pt(II)
complexes. In the second example, a Pt(IV) complex was prepared with a bromoacetate
ligand in the axial position. A less intense Br map was obtained following treatment of the
A2780 cells with the resultant Br-labelled Pt(IV) complex suggesting that reduction (and
dissociation of the axial Br ligands) occurred prior to cell uptake.[38-39]
Microprobe SRXRF imaging has been reported for thin sections obtained from a
tumour harvested from a mouse 3 h after injection with the Pt anti-cancer agent, cis, trans,
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cis-[PtCl2(OH)2(NH3)2)].[38] The study revealed Pt and Zn co-localization in one area of a
section of the tumour which the authors interpreted as corresponding to only one cell. The
authors commented that identifying an appropriate sample area for imaging was an
unexpected challenge.[38] Nonetheless, this could be an important area for future studies for
confirming the potential clinical usefulness of metal-containing therapeutics.
Pt-Gd complexes have also been studied using microprobe SRXRF to determine the
potential of these drugs for neutron capture therapy. Since

157

Gd possesses the largest

effective nuclear cross-section, Gd(III) complexes are ideal agents for thermal neutron
capture therapy employed for the destruction of tumour cells.[40]

As a mechanism of

achieving this, Rendina and coworkers[40] designed and synthesised the Pt-Gd complex that
incorporated the DNA intercalating moiety, [PtII(terpy)] (terpy = 2,2’:6’2’’-terpyridine).
Microprobe SRXRF of individual A549 human lung carcinoma cells treated with the Pt-Gd
complex (5 µM) for 24 h showed the colocalisation of the Gd and Pt in the Zn and P regions
of the cell which define the nucleus. Firstly, this result indicated that the Pt-Gd complex
remained intact inside the cells. Secondly, the finding that Gd and Pt accumulated in the
nucleus was extremely important since the effectiveness of Gd(III) neutron capture therapy
relies on the ability of the complex to localise in close proximity to critical cellular
components of the cancer cells.[40] In addition, statistical analysis of the intracellular K
concentrations showed K increases of approximately 10× those of the control cells. The
authors attributed this to: (i) a possible activation of Na+/K+ ATPase; (ii) the direct interaction
of the drug with potassium ion channels that effectively trap K+ in the cell; or (iii) the down
regulation of potassium ion channel expression by targeting chromosomal DNA; although
these hypotheses are yet to be confirmed.
In an extension of the aforementioned medicinal chemistry approach, Rendina and
coworkers[41] studied the cellular uptake of the Pt(II)-carborane complex where the same Pt
8

containing moeity, [PtII(terpy)], was attached to carborane, the latter being important as a
boron neutron capture therapeutic agent. In this instance, microprobe SRXRF was unable to
show aggregation of Pt within the nucleus despite high levels of Pt found in the cells
suggesting dissociation of the complex.[41]
Arsenic-Containing Anti-Cancer Drugs
Arsenic trioxide, marketed as Trisenox, was approved by the Food and Drug Administration
in 2000 for the treatment of relapsed acute promyelocytic leukemia (APL).[42] Its clinical
administration has been associated with a 65-80% complete remission rate.[42] This has
prompted research into its mode(s) of action with the important goal of refining its
administration and designing more efficacious As drugs for treatment of leukemias and solid
tumours.[43-45]
SRXRF has been used for monitoring As along the length of the hair of APL patients
receiving Trisenox treatment.[46] A beam (17 keV) of dimensions 10  3 µm2 was used to
scan 30-µm thick hair sections covering a length of 5 cm (corresponding to a period of 5
months hair growth).[46] The results demonstrated a rapid response of As content in the hair
that reflected the different treatment regimes.[46] For instance, the As content in the hair
showed expected fluctuations in a patient receiving non-continuous treatment over a period of
2 months.[46] In a more refined study led by the same author,[47] the X-ray beam (11.863 keV)
was focussed to 1  3 µm2 dimensions using a KB mirror and a sampling interval of 7 h was
used. A steep increase in As content was observed within 24 h and reached more that half the
maximum level.[47] The results were in agreement with the pharmacokinetics of rapid As
absorption and elimination.[47] It was also observed that the As was distributed on the
periphery of the cortex.[47] It was reported that this was similar to findings following external
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As contamination of the hair which meant that one could not distinguish between ingested As
or external As contamination based on its distribution through the cross-section of the hair.[47]
Microprobe SRXRF has also been used to probe the mechanisms of Trisenox therapy.
HepG2 human hepatoma cells were imaged following administration of arsenite (the soluble
form of Trisenox). Microprobe SRXRF showed that As accumulated in the euchromatin
region of the cell nucleus following exposure to relatively high doses of arsenite (1 mM, 4 h,
Figure 2).[32] This is consistent with As targeting DNA or proteins involved in DNA
transcription. Subsequent studies of HL-60 cells (APL cells) that had been administered
therapeutically relevant doses of arsenite (10 µM, 4 h) have also shown As localisation in the
nucleus, and in some cases the nucleolus.[48] Intracellular concentrations were too low to
confirm euchromatin localisation.[48]

The additional ability of microprobe SRXRF to

quantify intracellular elements was also highlighted in the article whereby differences in the
relative distributions of Ca within the nucleus and cytoplasm were correlated with As
treatment.[32] Increased nuclear Ca localisation was consistent with studies performed by
Yee-Chien and Haimei[49] who showed that arsenite treatment of CHO-K1 cells also triggered
Ca2+ accumulation. The ability of the technique to monitor intracellular Ca2+ is important
since the loss of Ca2+ homeostatic control is an indicator of apoptosis. In addition, toxic
agents that cause depletion in GSH (as is the case for arsenicals) can cause a concomitant
influx of Ca2+ and perturb the intracellular Ca distribution.[50]
DNA Metallointercalator Agents
Microprobe SRXRF has been important for the medicinal chemist for establishing “proof of
concept” with respect to the mode of action of particular drugs. A key example is the use of
microprobe SRXRF for studying the uptake of metallointercalators to determine whether the
complexes could target DNA, as intended in their design.[8] Figure 3 shows the microprobe
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SRXRF elemental maps of thin-sectioned cells obtained following the exposure of A549 lung
cancer cells to cisplatin, or the metallointercalators, [56MESS] ([5,6-dimethyl-1,10phananthroline(1S,2D-diaminocyclohexane)platinum(III)]) or [Ni(phen)(dppz)]2+ (phen =
1,10-phenanthroline, dppz = dipyrido[3,2-a:2’,3’-c]phenazine) for 4 h. Thin-sections (1 µm)
were mapped using a beam energy of 11.9 keV, focused to 0.2  0.15 µm2 using two zone
plates, and using a 0.3 µm step size (Beamline 2-ID-D, Advanced Photon Source, Argonne
National Laboratories). The results were promising, since the microprobe SRXRF studies
were the first to show that both Pt and Ni clearly localised in the cell nucleus following
treatment with [56MESS] or [Ni(phen)(dppz)]2+, respectively. Furthermore, it was clear that
the localisation occurred in the heterochromatin region of the nucleus; i.e., in the vicinity of
the densely packed DNA.[8]

Metallocene Anti-Cancer Agents
Microprobe SRXRF imaging of metallocene-treated V79 Chinese hamster lung cells was also
performed since it has been reported (over 30 years ago) that metallocene dihalide complexes
exhibit anti-tumour activity.[31,51] Complexes of the structure, Cp2MCl2 where Cp = 5cyclopentadienyl and M = Mo, Nb, Ti or V were studied to differentiate between the cellular
targeting properties of the specific metal complexes since DNA (specifically nucleic acid rich
regions of solid Erhlich ascites tumour cells) had been implicated as the primary target for
Cp2TiCl2 and Cp2VCl2, with Cp2TiCl2 undergoing phase I and II clinical trials. In contrast,
no data existed for the Mo and Nb complexes and it was important to evaluate whether these
complexes also possessed promising properties that warranted preclinical studies.[31]
Unfortunately, microprobe SRXRF analysis of whole cells that had been treated with IC50
concentrations of Cp2TiCl2 or Cp2VCl2 (100 µM and 10 µM, respectively, for 24 h) showed
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only small increases in the Ti and V concentrations that were not considered significantly
higher than the control cells using the Dunnett test.[31] It was concluded that the intracellular
concentrations must have been at the detection limit of the technique. In contrast, significant
increases in the intracellular Mo concentrations were obtained following treatment of the V79
cells with Cp2MoCl2 (800 µM, 24 h) or Cp2Mo(SC6F4COONa)2 (800 µM, 24 h).[31]
Similarly, increased cellular Nb was detected in cells treated with Cp2NbCl2 (250 µM, 24 h).
One of the greatest challenges of the study was the simultaneous detection of Mo and the
important endogenous elements, given that the use of the 20.5 keV beam for detection of Mo
resulted in poorer detection of the lower energy elements such as K, Cl, S, and P.[31] In
efforts to overcome this, dual mapping was performed at 10 keV and 20.5 keV using
coordinates generated from alphabetised Finder grids.[31]

The resultant images showed

colocalisation of Mo with K and Zn indicating the ability of Cp2MoCl2 to traverse the nuclear
membrane and accumulate in the nucleus.[31]
Nanoparticles and Nanoconjugates
A rapidly emerging area of medicinal chemistry is the use of nanoparticles as direct
therapeutic agents, drug delivery agents, and even diagnostic agents.[35,52-53] Consequently, it
is not surprising that microprobe SRXRF is becoming recognised as a technique for imaging
intracellular nanoparticles in efforts to develop and confirm the capabilities of these
agents.[35,52] An exciting study has been reported by Paunesku et al.[52] whereby they aimed
to produce DNA-targeting TiO2 nanoparticles that could be excited, causing the
electropositive holes of the semiconductor to be injected into the DNA, ultimately leading to
DNA scission. The important role of microprobe SRXRF was to establish whether these
nanoparticles could be taken up by the cells and retained at their target DNA sequence.[52]
Two DNA targets were studied, those of ribosomal RNA located in the nucleoli or the
mitochondria. It was shown that the different nanoconjugates were retained in detectable
12

quantities exclusively in the subcellular compartments that they were designed to target.[52]
The authors also used microprobe SRXRF to show that inclusion of the contrast agent,
Gd(III), into the nanoparticle to produce Gd(III)-modified DNA-TiO2 nanoconjugates, also
resulted in a structure capable of specific organelle targeting.[54] The interest in this result
was that the complex possessed the added ability of being detectable by magnetic
resonance.[54]

Hard X-Ray Fluorescence Tomography.
Plane-polarized XRF was proposed more than a decade ago for whole body imaging in order
to take advantage of the fact that XRF is a non-invasive technique, capable of highly sensitive
elemental analysis.[55] A typical and highly desirable application of the technique was to
image the platinum concentration associated with administration of the drug, cisplatin (or its
transplatin analogues).[55] The goal was to provide clinical information regarding its in vivo
distribution and in so doing, assist in establishing dose-response relationships, for optimising
and maximising therapeutic effect and minimising toxicity and cost.[55]

The minimum

detectable concentration (MDC) increased with increasing depth of the tumour due to the
attenuation effect. Also the estimated MDC’s ranged from 5.6-38.1 ppm depending on the
tumour depth (reported as 20-35 mm, respectively) and radiation dose applied.[55] A number
of challenges need to be overcome, however, before this becomes a more widely used
technique.
Microprobe XRF tomography has also been proposed as an exciting technique capable
of 3-D imaging of trace elements in biological tissues and cells whereby sub-500 nm
resolution XRF tomography is now possible. To date, SRXRF microtomography of bound Pt
in DLD-1 human colon carcinoma spheroids has successfully monitored the depth of
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penetration of cisplatin and three Pt(IV) complexes after 24 h exposure.[56] The technique
detected 10 ppm Pt in the cancer spheroids and showed enrichment of the Pt in the outer
region (corresponding to the outer proliferative region) and uniform distribution deeper
within the spheroid.[56] In addition, the study showed poorer but similar penetration profiles
of Pt(IV) complexes in comparison to cisplatin and represents an interesting future
mechanism for studying the efficiency of other anti-cancer agents.[56]
While not a medicinal chemistry application, de Jonge and Vogt[57] have performed
higher resolution imaging of the whole diatom, Cyclotella meneghiniana, with 150-nm
voxels over a 15-µm field of view. An exciting prospect of the technique would be the
incorporation of cryocapabilities which would enable the 3-D elemental analysis of frozenhydrated specimens. Biological tissues and cells analysed by this technique would require
minimal sample preparation, reducing concerns regarding the difficulties and artefacts
associated with sample preparation and serial thin-sectioning.[57]

Despite the exciting

promise of this technique, however, SRXRF microtomography has not yet found general
application. This is due to technical challenges combined with the required data acquisition
times, for e.g. de Jonge and Vogt[57] calculated that analysis of a 10 µm3 specimen, performed
at 30 nm resolution and 300 projections, would take 8 h. The consequential use of a smaller
sample size decreases the statistical power of the analysis and raises the question of the
reliability of any conclusions. Another challenge of SRXRF tomography, as alluded to in the
case of whole body analysis, is self-absorption.[55,57] Existing corrections of self absorption
assume that the X-rays are confined to and are absorbed only by the voxels within the imaged
specimen plane, which is unrealistic.[57] As such further progress needs to occur before this
technique can become routine and impact on medicinal chemistry research in the clinic.
Fortunately, self-absorption will be less significant with smaller samples, such as individual
cells.
14

X-Ray Absorption Spectroscopy
XAS is an important tool for studying most elements of the periodic table and it has been
extremely useful for studying transition metals and metalloids. It is specifically useful for
studying metals that are otherwise spectroscopically silent; i.e., those that possess filled or
empty d-shells and have no spectroscopic signature.[58] XAS is beneficial for the study of
bioinorganic systems such as metal- and metalloid-containing drugs and enzymes since it is
an extremely versatile and highly sensitive technique capable of providing information
regarding metals in many physical states and chemical environments.[58-60] The technique can
be applied to bulk or microprobe analyses of samples which include: solids, biological
solutions, electrophoresis gels, and healthy or diseased mammalian cells and tissue.[58-60]
XAS, in contrast to XRF spectroscopy, cannot feasibly be performed using a laboratory
X-ray source. Instead the highly intense and tunable X-rays generated at a synchrotron are
essential for XAS.[61] The instrumental setup for XAS is shown in Figure 4 where it is
apparent that XAS data can be collected in two modes: fluorescence mode or transmission
mode. Normally the technique is performed in transmission mode; however, in the case of
trace elemental speciation such as those associated with biological samples, (i.e. those of
dilute concentrations associated with proteins, bulk or single cells) the technique is often
performed in fluorescence mode since it imparts greater sensitivity.[61]
The principles for XAS are outlined briefly; however, the reader is referred to reviews
for a more detailed description.[58,62-65]

An X-ray absorption spectrum is generated by

subjecting the sample to a tuneable X-ray beam produced by a synchrotron source. The Xray beam energy is swept across an energy range that encompasses the binding energy of the
element of interest. When the X-rays have sufficient energy to eject a core electron to an
15

orbital (that is partially filled or empty) or to the continuum, there is an abrupt increase in the
absorption coefficient, which gives rise to the dominant feature of the XAS spectrum (Figure
5) known as the “absorption edge”.[58] The XAS spectrum can be divided into two main
regions: the X-ray absorption near edge structure (XANES) and extended X-ray absorption
fine structure (EXAFS) regions, which contain extremely useful information regarding the
local structural environment of the element of interest.[58]
The XANES spectrum is typically defined as the region immediately within
approximately 50 eV of the edge.

Key features of the XANES spectrum include the

aforementioned edge, and the white line peak which occurs directly after the edge. The
XANES spectrum is sensitive to the oxidation state, the immediate coordinating atoms, and
the electronic structure of the absorber atom.[58,62-63] It provides information regarding the
average coordination environment of the absorber atom and can be used to provide
qualitative information.[58,62-63] Typically, increases in the oxidation state are associated with
increases in the energy associated with the absorption edge, since greater energy is required
to eject the core electron.[58,62-63] Caution must be used when relying on the spectral edge
position to interpret the oxidation state, however, since the coordinating atoms also influence
the edge energy. For instance, while the oxidation state does not change, a slight decrease on
the local charge of the absorber element brought about by coordination to a less electronwithdrawing atom (e.g. S versus O) would result in a lower edge energy.[58] In addition, and
complementary to this, the edge energy can be influenced by the metal-ligand bond distance,
with the edge energy expected to vary inversely with the square of the metal-ligand
distance.[58] Another factor that is observed in the XANES spectrum is that the features
become broadened when the coordination environment becomes less symmetric, giving rise
to a less intense white line.[58] A typical example of this is the more symmetrical crystalline
small-molecule models compared with their protein- or peptide- bound analogues.[58] In
16

some cases a pre-edge peak is also observed. Weak pre-edge peaks for the K edge first row
transition metals are observed for the forbidden (dipole selection rules) 1s  3d transition.
They occur for metals that have an unfilled 3d shell and provide an indicator of coordination
geometry. For instance, the centrosymmetric octahedral Cr(III) complex exhibits the weakest
pre-edge feature, while the loss of centrosymmetry associated with trigonal bipyramidal and
tetrahedral complexes is associated with an increase in the intensity of the pre-edge peak.[6669]

This phenomenon is due to the mixing of the 3d and 4p orbitals and direct quadrupolar

coupling.[58,66]
The EXAFS spectrum extends to higher energies and contains more subtle features
(Figure 5). It results from the interaction of the ejected electron with the surrounding atoms
and is distinguished by a wavelike structure indicative of the constructive and destructive
interference from which it is generated.

For more detailed information regarding the

principles of EXAFS the reader is referred to the cited reviews.[8,58,64-65]
Both XANES and EXAFS have played essential roles in the analysis of proteins and
enzymes in cells. Micro-XANES/EXAFS utilises focusing devices (KB mirrors or zone
plates) that focus the beam to micron or submicron dimensions, enabling analysis of cellular
and subcellular structures.

To date micro-XANES analysis has provided information

regarding metals associated with diseased states, such as Fe(II/III) located in the neuronal
cells of subjects exhibiting Alzheimers and Parkinsons diseases,[70] Cu(I)/Cu(II) in
dopeminergic cells associated with Parkinson’s disease, and Zn concentrations associated
with prostate cancer.[70] The focus of the following sections, however, is on the use of
XANES and EXAFS (and the microprobe applications of these) to study the chemical
structure of therapeutic agents prior to and after cell uptake in order to probe their
biotransformations within cells.
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Platinum-Containing Anti-Cancer Agents
Both XANES and EXAFS have been used by medicinal chemists to characterise metalcontaining drugs in solution, formulations, and biological media.

Some of the most

prominent studies include those associated with the anti-cancer drug, cisplatin. Solutions of
the platinum-containing drug, cisplatin,[71] and its derivative, oxaliplatin,[72] have been
analysed by bulk XAS to confirm the presence of axial water ligands. Bulk XAS has also
been used for the development of controlled release drug delivery systems by confirming the
integrity of drugs in the delivery agent; a specific example being the use of XAS to confirm
that the structure of cisplatin did not alter following its incorporation into poly(ethylene
oxide) gel.[73]
Hambley and coworkers[33,74-75] used bulk XAS to determine the ability of Pt-treated
cancer cells to reduce Pt(IV) complexes to the potentially more active Pt(II) anti-cancer
agents. Predictably, the position of the edge assisted in the differentiation (2.2 eV difference)
of Pt(II) from Pt(IV).[33,74] So too did the ratio of the intensity of the white line peak to the
post-edge region.[33,74] In recent efforts to try to combat cisplatin resistance, Hambley and
coworkers[75] prepared monomeric Pt(IV) analogues, [trans,mer-[PtCl(OH)2] and [trans,mer[PtCl(dien)], of the potent polynuclear platinum complex, [trans-PtCl(NH3)2)2{µ-transPt(NH3)2(NH2(CH2)6NH2)2}]4+, since the latter complex had been withdrawn from phase II
clinical trials due to side effects (despite earlier promise).[75]

Human ovarian A2780

carcinoma cells were treated with the Pt(IV) drug and analysis of the XANES spectra with
respect to the standard curve, prepared from the ratio of the peak height to the post-edge
intensity for known ratios of Pt(II) to Pt(IV), was performed. It was found that 38% of the
drug had reduced to Pt(II) in the first 2 h while most of the drug (87%) had converted to
Pt(II) within 24 h. They concluded that the improved intracellular stability of the triammine
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complex highlights the importance of preparation and testing of the Pt(IV) polynuclear
complex.[75]
Arsenic-Containing Anti-Cancer Agents
In a pharmaceutical-directed study, Nicolis et al.[76], used XAS to characterise arsenic in the
injectible arsenic trioxide formulations used to treat APL patients. Unsurprisingly, XANES
spectroscopy showed that the As species was As(III) while EXAFS analysis indicated that the
arsenic was coordinated to three oxygen atoms at a distance of 1.779 Å, similar to arsenous
acid.[76] Nicolis, et al.[47] also performed XANES studies of As in the hair of APL sufferers
following Trisenox administration. They reported that the As was not S-bound but was O- or
N- bound. They attributed this finding to the fact that the cysteine residues of keratin are
engaged in cystine sulphur bridges.[47]
Multiple linear regression analysis of XANES spectra and EXAFS analysis of spectra
obtained from arsenite-treated HepG2 human hepatoma cells (100 µM, 4 h) were employed
to shed light on the As metabolites formed following high dose exposure. The predominance
of As tris-sulfur species provided increased credence to the likelihood that the dominant
interactions of As occurred with nuclear proteins and potentially act as a key factor in Asinduced cancer toxicity.[32]
Bacquart et al.[77] performed microprobe XANES of As located (by microprobe
SRXRF) in the nucleus, cytosol and mitochondrial network of arsenic trioxide-treated human
ovarian adenocarcinoma (IGROV1) cells. The instrumental set-up involved the use of a
liquid nitrogen cryo-stream to reduce radiation damage to the sample. It was found that the
predominant species in the IGROV1 cells, and that responsible for toxicity, was As(OH)3
since metabolism was negligible in the cell line.[77] In contrast, microprobe-XANES analysis
of HepG2 cells treated with As(OH)3 showed small edge energy shifts of the As XANES
19

spectra that were dependent on the organelles (average edge energies: arsenic trioxide,
11871.5 eV; nucleus, 11870.7 eV; cytosol and mitochondrial network, 11871.2 eV)
indicating differences in As speciation.[77] Exposure to low concentrations of arsenite (10
µM, for 24 h vs 100 µM, 4h in the study described above)[32,77] also resulted in predominance
of As(III), although there was some evidence of mixed valence As (As(III)/As(V)) in the
nucleus of one of the nine cells analysed.[77]
Other Anti-Cancer Agents
XANES analysis of intracellular cobalt has been important for the development of cobalt
complexes as potential hypoxia-activated prodrugs.[78-80] The concept was to exploit the
hypoxic nature of tumours whereby the inert Co(III) complexes could be reduced to the labile
Co(II) complexes in the reducing environment, and subsequently release an active anti-cancer
agent.[78-80] The XANES studies involved the systematic study of a mixture of Co(III) and
Co(II) complexes to differentiate between the oxidation states.[78] It was noted that the
analysis of Co in cells was complicated by changes in the coordination sphere of Co(III)
complexes, and that XANES was useful for monitoring the oxidation state as long as the
ligand exchange reactions of Co(III) were slow relative to the reduction to Co(II).[78] While
the XANES of intracellular Co obtained from [Co(diNOsar]Br3-treated cells reflected that of
the solution spectra of the complex, it was found that the spectra obtained from [Co(acac)3]and [Na[Co(acac)3]-treated cells reflected a mixture of intracellular products. indicating a loss
of the carrier ligands .[80]
EXAFS in conjunction with the new synchrotron based technique, nuclear resonance
vibrational spectroscopy (NRVS), and density functional theory calculations was used to
probe the anti-cancer mechanisms of the glycopeptide, bleomycin.[81]

Bleomycin is an

effective chemotherapeutic agent used to treat Hodgkins lymphoma and head, neck, and

20

testicular cancers. It is believed to complex to Fe in vivo to facilitate DNA double strand
scission via a reaction of FeIIIBLM with O2 and an electron, or through a shunt reaction
between FeIIBLM and H2O2.[81] Following the study, it was concluded that the active species
were (BLM)FeIII-OH and (BLM)FeIII(1-OOH) and that direct H-atom abstraction is the
thermodynamically favoured pathway over other proposed pathways.[81]
Anti-Malarial Drugs
EXAFS of Fe has also been conducted to improve the understanding of the mechanism of
action of the anti-malarial drug, chloroquine.[82]

It is known that malaria parasites are

susceptible to quinoline based drugs only at the time of hemoglobin degradation and
production of malarial pigment.[82] The parasite digests the peptide chains of the host’s
hemoglobin and needs to dispose of the remaining heme to avoid toxicity and death of the
parasite. It is believed that quinoline drugs complex to the resultant heme and prevent their
disposal. Walczak et al

[82]

claimed that, it was impractical to directly study infected blood

samples from patients treated with chloroquine, given the fact that there is Fe associated with
hemoglobin as well as the heme remaining from the parasites’ digestion. Consequently, they
performed XAS of the synthetic substitute, mesohematin anhydride, in acidic solvent (to
simulate the parasite’s food vacuole) in the presence of the drug.

[82]

They observed

differences between the synthetic equivalent of hemozoin in the powder state compared to the
aqueous state (in acetic acid and water) at different concentrations that mimicked the
physiological condition of the parasite’s food vacuole.

Additional changes were also

observed following the addition of the anti-malarial drug, chloroquine.[82]
Anti-Inflammatory Agents
One of the earliest medicinal chemistry uses of XAS was the study of the biotransformation
products of gold-based rheumatoid arthritis drugs.[83] Aurosomes isolated from Sprague21

Dawley rats that had been injected (intraperitoneally) with sodium gold(I)thiomalate (0.4 mg
Au/kg, weekly for 20 weeks) or gold(III) tetrachloride (35 mg Au/kg, single dose) were
analysed using XANES.[83]

XANES spectra revealed that the gold associated with the

aurosomes following treatment with sodium gold(I)thiomalate was Au(I).[83] In addition,
Au(I) was also identified in the aurosomes of rats that had been treated with gold(III)
tetrachloride indicating the in vivo reduction of Au(III).[83] EXAFS analysis revealed that the
Au resulting from administration of gold(I)thiomalate was coordinated to two sulfur atoms
which were believed to be of cysteine (protein) or glutathione origin.[83] While reported in
the context of Au anti-proliferative agents, Messori et al. recently performed XAS studies of
the interactions of auranofin with the human plasma proteins, bovine serum albumin and
serum apotransferrin.[84] The Au(I) oxidation state was conserved during protein binding and
the mechanism was believed to occur through release of the thiosugar ligand to facilitate
replacement with a thiol or thioether from the protein.[84]
The use of XAS for the development of copper containing NSAIDs, such as
[Cu2(indo)4L2], indo = (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate) and L
= solvent ligands, played a crucial role in the development of veterinary and human
nonsteroidal anti-inflammatory formulations, the latter proceeding to human clinical trials.[85]
XAS was used to explore the chemical and physical properties of the formulations with
emphasis on modelling the dimeric Cu2O10C8 core in the dimeric Cu(II) complex and
examining any changes in it as a result of changes in the axial ligands.[85] The flexibility of
the technique for analysing injectable formulations, gels, ointments, and pastes highlights its
usefulness for characterising pharmaceuticals for registration. Similarly, EXAFS was also
applied for the successful characterisation of mononuclear and dinuclear zinc-indomethacin
complexes.[86]
Ruthenium Anti-Metastatic Agents
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Emerging drugs (in phase I clinical trials) such as the potential Ru(III) chorido-indazole anti
cancer drug (KP1019) and the anti-metastatic agent, NAMI-A,[87-88] have been analysed in
cell culture media, blood serum and cultured mammalian cells to understand the
transformations that occur to the metal centre. Lay and coworkers[89] isolated Ru(III)-BSA
complexes by gel-filtration chromatography, freeze-dried the product and analysed it by
XAS.[89] The resultant spectra were compared with the parent Ru(III) complex, and model
Ru(III) complexes containing predominantly Cl, NH3, or CH3COO ligands.[89] Linear
regression analysis of the post-edge regions of the XANES spectra revealed that the Ru(III)BSA spectrum was best characterised by a model consisting of 65% Ru bound to N, and 35%
Ru bound to O, suggesting replacement of the original Cl ligands with protein N-donors and
carboxylato residues.[89]

The authors concluded that the XAS evidence, suggesting that

>90% of the Ru(III) complex binds to blood albumin, is consistent with its low toxicity but
high anti-metastatic efficacy.[89]
Dietary Supplements
Multiple linear regression analyses of XANES spectra have been used for characterisation of
Cr(III) anti-diabetic supplements including [Cr3O(OCOEt)6(OH2)3]+, [Cr(pic)3] (pic = 2pyridinecarboxylato) and trans-[CrCl2(OH2)4]+ (introduced as CrCl3.6H2O) in biological
fluids and in cultured cells.[90] It was found that [Cr3O(OCOEt)6(OH2)3]+ and [Cr(pic)3]
underwent extensive ligand exchange reactions in solutions that simulated gastric and
intestinal conditions and in the presence of blood serum and cell culture medium.[90] The
resultant products were identified as Cr(III) complexes coordinated to hydroxo and amino
acid ligands.[90] Concern was raised over the finding that reactions of [Cr(pic)3] with serum
enhanced its propensity to be converted to carcinogenic Cr(VI) by biological oxidants.[90]
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The speciation of common selenoamino acid supplements, selenomethionine (SeMet)
and Se-methylselenocysteine (MeSeCys) in A549 human lung cancer cells has also been
investigated using XAS.[91] The value of this research stems from the fact that the essential
element, Se, has been linked to reductions in the cancer incidence and mortality when
administered at supranutritional doses.[91] MeSeCys is believed to be the more effective
chemopreventative agent of the two complexes since MeSeCys is known to produce MeSeH
more efficiently than SeMet.[91] Linear combination fitting of the XAS spectra of the Se
standards to those obtained from the cell pellets treated (24 h) with the supplements showed
that Se was found exclusively in the carbon bound form in SeMet-treated cells while a
diselenide component was also identified in MeSeCys-treated cells, indicating that there was
a difference in the metabolism of the supplements.[91] It was suggested that the presence of
the diselenide component in the MeSeCys-treated cells may be due to the cleavage of
MeSeCys by -lyase to produce the active anti-carcinogenic compound, MeSeH.[91]

Synchrotron Radiation – Fourier Transform Infrared Microspectroscopy
The application of vibrational spectroscopy for the detection of disease in human tissue and
cells commenced in the early 1990’s and escalated following the development of lab-based
and later, synchrotron radiation-based infrared microspectroscopy.[92] There have since been
significant developments towards disease diagnosis, improvements in the understanding of
disease progression and validations of hypotheses regarding diseases such as prostate,[93]
skin,[94] colon,[95] cervical,[94,96] and breast cancers,[97] melanoma,[98] leukemia,[99]
transmissible spongiform encephalopathies/prion diseases,[100] Alzheimers disease,[101-102]
diabetes,[103] malaria,[104] ophthalmic disorders,[105] and arthritic disorders.[94,99]
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The usefulness of SR-FTIR microspectroscopy derives from the fact that the IR source
is 10-1000 times more brilliant than the conventional globar source.[106-107] This equates to
superior signal to noise ratios in the resultant spectra, improving acquisition times and spatial
resolution, both of which are important for analysing biological samples.[92,106] As such,
recent attention has been focussed on the use of SR-FTIR microspectroscopy for the study of
biomolecular changes that occur following the administration of drugs or potential
therapeutic agents in diseased cells.[92,108-112] Importantly, macromolecules associated with
biological samples produce signature IR bands that can be readily discerned from the IR
spectra.[94,99,113-114] Typical spectral features include: amide I ( 1650 cm1) and amide II (
1549 cm1) bands representative of proteins; symmetric (1080 cm1) and anti-symmetric
PO2 (1232 cm1) bands associated with DNA; C-H stretches of –CH3 (as 2955 cm1) and
–CH2 (as 2850 cm1), the ester band (1740 cm1) and the C-O-P (1080 cm1) band
associated with lipids/phospholipids; and C-O stretches (1050 cm1) of carbohydrates.[94,99,113114]

In addition, changes in the average protein secondary structure can be detected by

analysing the components of the amide I band. For instance, specific secondary structural
assignments include: -helices (1645-1662 cm1), -sheets (1613-1637 cm1), turns (16621682 cm1) and random coils (1637-1645 cm1).[99,113,115-117]
A recently emerging medicinal chemistry application of SR-FTIR microspectroscopy is
the analysis of fixed and live cancer cells to detect biomolecular changes that occur following
drug treatment. The interest in the use of this technique stems from an urgent demand for the
development of accurate and cost-saving analytical techniques that can be applied to the
screening of new drug candidates.[109] The analysis involves the collection of spectra from
large numbers of cells (generally >100 cells per sample) following exposure to the
therapeutic agent, and the objective analysis of the resultant data through statistical
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procedures such as principal component analysis (PCA) and hierarchical cluster analysis.[92]
While changes in spectral features can often be visually observed in average spectra, tools
such as PCA remove subjectivity and add credence to the evaluation of any biomolecular
differences/similarities in the spectra of cell or tissue samples.[118] SR-FTIR can be used for
mapping individual cells and tissues;[119-120] however, this is diffraction limited and noise
becomes apparent at approximately 1000 cm1 when an aperture of 5 µm2 or smaller is
used.[106] Currently, there a a number of new promising developments in progress to try and
overcome this limitation as described within the cited review.[24]
One of the most important challenges of SR-FTIR analysis of single cells is overcoming
issues of highly distorted baselines, and derivative-like peak shapes, which are associated
with small (<10 µm) cells and specifically affect strong bands such as the amide I band.[92,107]
In an effort to try to separate biochemical-induced effects from those of the physical shape
and size of the cells that lead to the IR baseline abnormalities, Gardner and coworkers have
developed correction algorithms that reduce the distortions caused by resonant Mie
scattering.[92,107,121] These have been implemented in a number of studies.[92,122-124]
Anti-Cancer Agents
A typical example of the use of SR-FTIR microspectroscopy for monitoring therapeutic
effects was the study of the spectral changes on non-small cell lung cancer cells (Calu-1)
following administration with cytostatic doses (0.1-100 nM) of the anti-tumour drug,
gemcitabine, for 24-72 h.[108] The study showed complimentarity between spectra obtained
from individual cells using SR-FTIR versus those obtained from bulk cell populations using a
conventional laboratory IR.[108] Hierarchical cluster analysis of spectral windows showed
dose- and time-dependent effects of the drug. Draux et al.[108] reported increases in the
molecular vibrations corresponding to characteristic bands of proteins and RNA and it was
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concluded that these IR changes may be related to the molecular mechanism of the cytostatic
drug and the accumulation of the cells in G1 phase.[108]
Bellisola, et al.[109] performed SR-FTIR microspectroscopy of chronic myeloid
leukaemia (K562) cells to identify signatures of apoptosis following administration of a drug
that directly targets the BCR/ABL oncogene protein, imatinib mesylate (4-[(4methylpiperazin-1-yl)methyl)-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2yl)amino]phenyl]benzamide), and a drug that indirectly targets the BCR/ABO oncogene protein,
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride). The authors
performed complimentary techniques such as Western Blotting analysis and were able to
identify and cross-validate some IR signatures induced by the imatinib mesylate in the K562
cells.[109] For instance, they concluded that significant changes that occurred in the interval
1290-900 cm1 and in particular between 940-900 cm1, were associated with changes in the
PO stretching mode in the phosphorylated proteins.[109] This was significant because the drug
was known to cause a rapid decrease of protein tyrosine phosphorylation.[109]
Mantsch and coworkers[125] have also used SR-FTIR microspectroscopy for the
detection of apoptosis in K562 cells and the T-lymphoblastic cell line (CEM cells), with the
aim of determining its feasibility as an indicator of chemosensitivity of leukaemia cells
isolated from individual patients. They noted greater changes in the CEM cells (52.8%)
versus K562 cells (15.67%) after 24 h exposure to the drug, etoposide, and found excellent
correlation with the percentage of apoptosis observed by flow cytometry results.[125] It was
also concluded that SR-FTIR microspectroscopy was able to detect apoptosis after 4 h
compared to 6 h using flow cytometry.[125]
SR-FTIR microspectroscopy was performed on A2780 ovarian cells that had been
treated with a new di-gold(I) organometallic complex, [1,3-(Ph3PAu)2C6H4], that was found
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to exhibit cytotoxic activity in vitro.[92] The interest in the drug stemmed from the fact that it
induced little to no resistance against cisplatin resistant cells which implied that the drug
acted by different mechanism(s).[92] Following the application of Mie scatter correction,
there was significant differentiation between the cell spectra obtained on treatment with
different drugs which fitted with different in vitro cell culture behaviour.[92] PC2 differences
were observed following the comparison of the control versus cisplatin or cisplatin versus
[1,3-(Ph3PAu)2-C6H4]-treated cells.[92]
Photodynamic Therapeutic Agents
Another example where SR-FTIR has been used for the evaluation of therapeutic effects
includes the area of photodynamic therapy (PDT).[111] PDT is based on the interaction of
light with a photosensitiser which, in turn, results in the production of radical species that
induce the death of cells in close proximity. For instance, PDT has potential for treatment of
cancerous cells (e.g., skin cancers) and infectious organisms.[111] Chio-Srichan et al.[111]
studied the effect of Hypocrellin A in HeLa cells as a function of incubation time since it
reportedly possessed anti-cancer activity when irradiated with light. PCA of the SR-FTIR
spectra obtained from cells administered Hypocrellin A followed by irradiation (10 J cm2
dose at 460 nm) revealed changes in the protein secondary structures, whereby a shift of the
amide I band from 1650 cm1 to 1630 cm1 was attributed to a contribution of increased
secondary -sheet structure.[111]

Decreases in the peaks in the region 1000-1300 cm1,

associated with DNA, were also observed.[111] This was attributed to a higher optical density
of condensed DNA, consistent with transmission electron microscopic evidence.[111]
The PDT potential of 4,5-benzoindotricarbocyanine (indocyanine green, ICG) as a
treatment for human melanoma was also assessed by SR-FTIR microspectroscopy.[112]
Previously, the poor success of PDT with melanomas was believed to stem from their high
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content of melanin which acts as a screen for white light. Consequently, ICG was proposed
since it absorbs light in the range 700-800 nm, where melanins do not absorb. SR-FTIR
analysis was performed on human skin melanoma cells (Sk-Mel-28) treated with ICG
followed by PDT.[112] Cluster analysis of the resultant IR spectra revealed a decrease in the
nucleic acid phosphate absorption modes at 1240 and 1180 cm1 in the ICG/PDT-treated cells
which was consistent with DNA fragmentation of the apoptotic cells.[112] Additionally, there
were protein conformational changes associated with protein denaturation and increases in
the lipid bands suggesting redistribution of the phospholipids within the cell membrane (i.e.,
externalisation of phosphatidyl serine).[112]
Live Cell SR-FTIR Microscopic Analysis
Although an experimental challenge, live cell analysis under aqueous media is desirable as it
removes the potential for spectral artifacts resulting from fixation procedures and provides
the added advantage of allowing real time analyses.[110,126-128] SR-FTIR microspectroscopy
was used to analyze live leukemia cells following their exposure to Trisenox, administered
in the form of sodium arsenite (100 µM).[110]

The procedure involved the use of a

demountable liquid cell comprising a 1-mm thick CaF2 window onto which a spacer had been
patterned by polymer spin coating and UV photolithography, and an upper 0.5-mm thick
CaF2 window (Figure 6A).[110,126] The two windows were held tightly together in a Thermo
micro compression cell (Figure 6B) in order to reduce the aqueous sample volume. The
design of the sample holder enabled the collection of high quality spectra from a solution that
was less than 20 µL. This meant that the spectra were not dominated by OH deformation
(Figure 6D).[110,126] Exposure of the HL-60 cells to the anti-leukemia drug resulted in
significant spectral differences within 40 min exposure. The most prominent differences (as
determined by the second derivative spectra and PCA) occurred in the protein region of the
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spectrum, where the dominant contribution to the amide I band shifted from 1639 cm1 (sheet) in the control cells to 1650 cm1 (-helix) in the arsenite-treated cells.[110] The overall
results of this study indicated that the mechanisms of action of arsenite-induced toxicity
involved alterations to the protein structure and interactions with DNA.[110]
One of the drawbacks of the demountable liquid cell described above was the slow loss
of the media, over the period of 2 h, limiting long term exposures and data collection.[110,126]
Subsequent improvements to the design have been made whereby the lithography fabricated
spacer has been changed from a single outlet channel to three zig-zag channels (Figure 6C),
which effectively slow down the loss of the solution.[126] An alternative live cell sample
holder was reported by Holman et al.,[128] which was a custom made on-stage mini incubator.
It allowed in situ SR-FTIR collection of spectra from cells while maintaining a proper
moisture and growth environment.[128] Clearly, the success of such devices, which enable
long term monitoring of the sample, will provide invaluable insights into the mechanisms and
kinetics of drug-induced cell modifications.
Combination of SR-FTIR and Fluorescence Microscopy for Simultaneous Analysis
The combination of SR-FTIR microscopy with fluorescence microscopy at the same
beamline was documented in 2002.[102] For the first time, an IR microscope had been
modified to allow simultaneous fluorescence sample visualisation and IR analysis.[102] The
capabilities were exploited for experiments ranging from studies of osteoporosis, to
Alzheimer’s diseased brain tissue, to cell apoptosis.[102]

The most sophisticated of the

experiments was the study of the effect of the drug, nandrolone decanoate (an anabolic
steroid that enhances bone density in osteoporotic women) in female monkeys that had
undergone ovariectomies to induce osteoporosis.[102,129] The monkeys were administered
different fluorochrome labels at 1 (calcein) and 2 years (alizarin) after the ovariectomy, to
30

identify the new bone using fluorescence microscope. The areas were analysed by SR-FTIR
microspectroscopy and the phosphate/protein ratio was studied with reference to control
monkeys. The results showed a reduced rate of bone mineralisation in ovariectomised
monkeys versus the control.

Furthermore, the mineralisation was also effected in the

monkeys treated with nandrolone decanoate.[129]
Conclusions
It is clear that synchrotron radiation techniques have provided, and will continue to provide,
important information to the medicinal chemist. Microprobe SRXRF has proven itself as a
technique for providing unequalled information regarding the distribution of metal and
metalloid-containing drugs in cells and tumours at subtoxic and therapeutic doses.[8,26,3132,38,40-41,56]

Targets such as the nucleus,[26,38] including the euchromatin[32] and

heterochromatin[8] regions, nucleoli,[32,48,52] membranes, and mitochondria[52] can be
identified as sites of localisation following studies of existing and potential therapeutic and
diagnostic agents. The technique has been invaluable for confirming theories of drug actions
(namely, the coordinative action of cisplatin and its analogues)[38-39] and for confirming
concepts associated with the modes of action of designed therapeutics (namely, confirmation
of drug penetration to the site of dense DNA).[8,40] In addition, microprobe SRXRF has been
used to determine whether potential therapeutic agents remain intact[40] or dissociate
following cell uptake.[41] The additional quantitative analysis of endogenous elements has
become significant for probing changes to the homeostasis of the cells as exemplified in the
studies of Ca changes associated with As uptake,[32] and intracellular K fluctuations following
the uptake of Pt-Gd complexes.[40] Detection of subtle changes in the concentrations and
distributions of endogenous cations or anions can provide invaluable information regarding
apoptosis and other modes of drug action.
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XAS has played a pivotal role in the structural analysis of therapeutic agents. It has
been essential for confirming/elucidating the structure of newly prepared complexes,[85] and
determining the fate of these complexes in biological solutions.[89] Not only has this given
insight into the mechanisms of their action, but it has also helped to understand why some
therapeutic agents might, or have shown, lower than expected efficacy.[85] The use of XAS
for bulk cell analysis has provided insight into the metabolism of therapeutic agents and
supplements[32,77,91] informing the medicinal chemist of expected products in vivo to be
exploited for further design purposes or for progression to animal studies and human clinical
trials.
Finally, the use of SR-FTIR microspectroscopy for studying the biomolecular effects of
drugs in vivo and in cell culture has become prominent in the last 5 years with studies of anticancer drugs,[92,108-109,125] osteoporosis drugs,[102] and photodynamic therapeutics[111-112]
showing distinguishable biomolecular changes. Issues associated with Mie scatter distortion
of the spectra are being addressed,[92,122-124] and the technique is being critically assessed with
a goal to using it for preclinical and clinical evaluation of drug candidates.[92,109,125] Clearly,
major advances in the design of live cell sample holders will also aid in the study of
therapeutic agents.[110,126-128]
In conclusion, it is anticipated that these synchrotron radiation spectroscopic techniques
will play a major role in medicinal chemistry in the future especially as improvements in the
instrumentation associated with the techniques evolves.
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Figure Captions

Figure 1.

Physical events associated with XRF spectroscopy that lead to the emission of
characteristic X-rays. Allowed electronic transitions that give rise to characteristic Xray lines are shown. E = Energy; BE = Binding Energy. Reprinted from: Chapter 11.
Synchrotron radiation X-Ray spectroscopy for investigations of intracellular
metallointercalators: X-ray fluorescence imaging and X-ray absorption spectroscopy,
Dillon, C. T. in Metallointercalators. Synthesis and techniques to probe their
interactions with biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.1, p 275,
Springer-Verlag/Wien, with kind permission from Springer Science and Business
Media B.V.

Figure 2.

Microprobe SR-XRF maps of P, S, Cl, K, Ca, Zn, Cu and As obtained from a thinsectioned HepG2 cell that had been treated with arsenite (1 mM, 4 h). Scan
dimensions: 20 × 20 µm, stepsize: 0.3 µm, dwell time: 3 s/pt. Reprinted with
permission from: Munro, K. et al.; Chem. Res. Toxicol., 2008, 21, 1760-1769.
Copyright 2008 American Chemical Society.

Figure 3.

Microprobe SRXRF elemental maps of A549 cells following treatment with : (A) cell
media only; (B) Ni(phen)2(dppz)]2+ (960 µM), or (C) [Pt(56MESS)] (490 µM). The
elements are specified at the bottom of each column. Operating conditions include:
Beam energy = 11.9 keV, Beam size = 0.2 µm × 0.15 µm; Stepsize = 0.3 µm; Dwell
time = 3 s/pt and Scan dimensions (H × V) = (A) 9 µm × 10 µm; (B) 14 µm × 14 µm
(C) 10 µm × 10 µm. Reprinted from: Chapter 11. Synchrotron radiation X-Ray
spectroscopy for investigations of intracellular metallointercalators: X-ray
fluorescence imaging and X-ray absorption spectroscopy, Dillon, C. T. in
Metallointercalators. Synthesis and techniques to probe their interactions with
biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.5, p 287, Springer-Verlag/Wien,
with kind permission from Springer Science and Business Media B.V.

Figure 4.

Experimental setup employed for XAS data collection. Reprinted from: Chapter 11.
Synchrotron radiation X-Ray spectroscopy for investigations of intracellular
metallointercalators: X-ray fluorescence imaging and X-ray absorption spectroscopy,
Dillon, C. T. in Metallointercalators. Synthesis and techniques to probe their
interactions with biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.7, p 293,
Springer-Verlag/Wien, with kind permission from Springer Science and Business
Media B.V.

Figure 5.

Typical XAS spectrum defining the XANES and EXAFS regions and showing typical
spectral features. Reprinted from: Chapter 11. Synchrotron radiation X-Ray
spectroscopy for investigations of intracellular metallointercalators: X-ray
fluorescence imaging and X-ray absorption spectroscopy, Dillon, C. T. in
Metallointercalators. Synthesis and techniques to probe their interactions with
biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.6, p 290, Springer-Verlag/Wien,
with kind permission from Springer Science and Business Media B.V.

Figure 6.

Live cell sample holder (A-C) including the two spacers (A and C) and the entire
holder (B). Resultant live cell spectra are shown (D) and include SR-FTIR averaged
spectra from HL60 control cells (40 min, −, n=23) and HL60 cells treated with 100 µM
arsenite: 40 min (−, n=20), 60 min (−, n=20), 100 min (−, n=18) and 120 min (− ,
n=15).[92,107]
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